Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Domingo Orozco-Beltrán, Edurne Lecumberri-Pascual, Jose A. Quesada, Oscar Moreno-Pérez, Manuel A. Ruiz-Quintero, Francisco J. Pomares-Gómez, Esteban Jodar-Gimeno, Carlos Pardo-Ruiz, Isabel Mascarell-Martinez, Rosa M. Mirete-López, Borja Morant-Bes, Jose M Borrachero-Guijarro, Miriam Zapatero-Larrauri, Maria Carmen Aparicio-Egea, Carmen Paniagua-Merchán, Rosa M. Requena-Ferrer, Elena Caride-Miana, Antonio Fernández-Giménez, Adriana López-Pineda, Rauf Nouni-García, Concepción Carratalá-Munuera & Ana M. Cebrián-Cuenca. (2023) Psychometric properties of the Clarke questionnaire for hypoglycemia awareness in the Spanish population with type 2 diabetes. Postgraduate Medicine 135:2, pages 141-148.
Read now
Read now
Ip Tim Lau, Ka Fai Lee, Wing Yee So, Kathryn Tan & Vincent Tok Fai Yeung. (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 10, pages 273-284.
Read now
Read now
Jodi Strong, Davida Kruger & Lucia Novak. (2017) Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Current Medical Research and Opinion 33:4, pages 785-793.
Read now
Read now
Mehul R. Dalal, Mahmood R. Kazemi & Fen Ye. (2017) Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization. Current Medical Research and Opinion 33:2, pages 209-214.
Read now
Read now
William H Polonsky & Robert R Henry. (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence 10, pages 1299-1307.
Read now
Read now
Bruno Detournay, Serge Halimi, Julien Robert, Céline Deschaseaux & Sylvie Dejager. (2015) Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vascular Health and Risk Management 11, pages 417-425.
Read now
Read now
Janice MS Lopez, Kathy Annunziata, Robert A Bailey, Marcia FT Rupnow & Donald E Morisky. (2014) Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. Patient Preference and Adherence 8, pages 683-692.
Read now
Read now
Lotta Walz, Billie Pettersson, Ulf Rosenqvist, Anna Deleskog, Gunilla Journath & Per Wändell. (2014) Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. Patient Preference and Adherence 8, pages 593-601.
Read now
Read now
Morgan Bron, Annie Guerin, Dominick Latremouille-Viau, Raluca Ionescu-Ittu, Prabhakar Viswanathan, Claudia Lopez & Eric Q. Wu. (2014) Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. Journal of Medical Economics 17:9, pages 646-657.
Read now
Read now
Stanley Schwartz. (2014) Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine 126:3, pages 66-84.
Read now
Read now
Sosale R. Aravind. (2014) Adding a DPP-4 inhibitor to metformin therapy may be safer than you think. Current Medical Research and Opinion 30:5, pages 791-794.
Read now
Read now
Pamela Maffioli & Giuseppe Derosa. (2014) Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. Current Medical Research and Opinion 30:5, pages 771-773.
Read now
Read now
Matthew L. Mintz & Gianmaria Minervini. (2014) Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia. Current Medical Research and Opinion 30:5, pages 761-770.
Read now
Read now
Lin Xie, Wenhui Wei, Chunshen Pan & Onur Baser. (2013) Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. Journal of Medical Economics 16:9, pages 1137-1145.
Read now
Read now
Articles from other publishers (50)
Omid Mehrpour, Farhad Saeedi, Samaneh Nakhaee, Farbod Tavakkoli Khomeini, Ali Hadianfar, Alireza Amirabadizadeh & Christopher Hoyte. (2023) Comparison of decision tree with common machine learning models for prediction of biguanide and sulfonylurea poisoning in the United States: an analysis of the National Poison Data System. BMC Medical Informatics and Decision Making 23:1.
Crossref
Crossref
Chung-Yi Li, Chia-Lun Kuo, Ya-Hui Chang, Chin-Li Lu, Santi Martini & Wen-Hsuan Hou. (2022) Association Between Trajectory of Severe Hypoglycemia and Dementia in Patients With Type 2 Diabetes: A Population-based Study. Journal of Epidemiology 32:9, pages 423-430.
Crossref
Crossref
Diane Merino, Alexandre Olivier Gérard, Susanne Thümmler, Nouha Ben Othman, Delphine Viard, Fanny Rocher, Alexandre Destere, Elise Katheryne Van Obberghen & Milou-Daniel Drici. (2022) Drug-Associated Parosmia: New Perspectives from the WHO Safety Database. Journal of Clinical Medicine 11:16, pages 4641.
Crossref
Crossref
Xi Tan, Lingfeng Yang, Kamlesh Khunti, Ruya Zhang, Ye Zhang, Swapnil Rajpathak & Miao Yu. (2021) Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States. Diabetes, Obesity and Metabolism 23:10, pages 2251-2260.
Crossref
Crossref
Gaetano Leto, Ilaria Barchetta, Lorenzo De Candia, Maria Grazia Magotti, Marco Cianciullo, Roberta Manti, Carlo Negri, Vincenzo Cimino, Alessandro R. Dodesini, Francesco Zerella & Roberto Baratta. (2021) Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy. Diabetes Therapy 12:10, pages 2645-2661.
Crossref
Crossref
NesmaAli Ibrahim. (2021) Frequency and predictors of hypoglycemia in Type 2 diabetes: A population-based study. Journal of Diabetology 12:2, pages 157.
Crossref
Crossref
Hassan Alwafi, Alaa A. Alsharif, Li Wei, Dean Langan, Abdallah Y. Naser, Pajaree Mongkhon, J. Simon Bell, Jenni Ilomaki, Mansour S. Al Metwazi, Kenneth K.C. Man, Gang Fang & Ian C.K. Wong. (2020) Incidence and prevalence of hypoglycaemia in type 1 and type 2 diabetes individuals: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 170, pages 108522.
Crossref
Crossref
Jakub Svěcený, Jana Jirušková, Karel Hrach, Lucie Radovnická & Jiří Laštůvka. (2020) Sulfonylurea derivatives and risk of hypoglycaemia in type 2 diabetic patients. Vnitřní lékařství 66:6, pages e35-e42.
Crossref
Crossref
Pamela R. Kushner & Davida F. Kruger. (2020) The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring. Clinical Diabetes 38:4, pages 348-356.
Crossref
Crossref
Melanie J. Davies, Cristina Bianchi & Stefano Del Prato. (2020) Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism 107, pages 154242.
Crossref
Crossref
Kohei Kaku, Koichi Kisanuki, Mari Shibata & Takashi Oohira. (2019) Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. Drug Safety 42:11, pages 1311-1327.
Crossref
Crossref
Beatriz Rodríguez-Sánchez, Talitha L. Feenstra, Henk J. G. Bilo & Rob. J. M. Alessie. (2019) Costs of people with diabetes in relation to average glucose control: an empirical approach controlling for year of onset cohorts. The European Journal of Health Economics 20:7, pages 989-1000.
Crossref
Crossref
Carol Baines, Geraldine O’Rourke, Charne Miller, Karen Ford & William McGuiness. (2019) Patient reported experience of blood glucose management when undergoing hyperbaric oxygen treatment. Collegian 26:4, pages 428-434.
Crossref
Crossref
Suzanne V. ArnoldSilvio E. InzucchiJustin B. Echouffo-TcheuguiFengming TangCarolyn S.P. LamLaurence S. SperlingMikhail Kosiborod. (2019) Understanding Contemporary Use of Thiazolidinediones. Circulation: Heart Failure 12:6.
Crossref
Crossref
Bruno Guerci, Neha Chanan, Simarjeet Kaur, Juan Guillermo Jasso-Mosqueda & Elisheva Lew. (2019) Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes. Diabetes Therapy 10:2, pages 437-449.
Crossref
Crossref
Louis Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol H. Wysham, Lone Nørgård Troelsen, Signe H. Østoft & Athena Philis-Tsimikas. (2019) Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial. Clinical Diabetes 37:1, pages 73-81.
Crossref
Crossref
Richard F. Pollock, William J. Valentine, Steven P. Marso, Jens Gundgaard, Nino Hallén, Lars L. Hansen, Deniz Tutkunkardas & John B. Buse. (2018) DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy 9:3, pages 1217-1232.
Crossref
Crossref
Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel & Sylvie Perreault. (2017) Association Between Metformin Adherence and All-Cause Mortality Among New Users of Metformin: A Nested Case-Control Study. Annals of Pharmacotherapy 52:4, pages 305-313.
Crossref
Crossref
Martin Haluzik, Adam Kretowski, Krzysztof Strojek, Leszek Czupryniak, Andrej Janez, Peter Kempler, Michal Andel, Tsvetalina Tankova, Mihail Boyanov, Lea Smircic Duvnjak, Laszlo Madacsy, Iwona Tarnowska, Marcin Zychma & Nebojsa Lalic. (2018) Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. Diabetes Therapy 9:2, pages 727-741.
Crossref
Crossref
Cristiano S. Moura, Zale B. Rosenberg, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli & Louise Pilote. (2018) Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy. Journal of Diabetes Research 2018, pages 1-7.
Crossref
Crossref
Carrie Palmer. (2017) Providing self-management education to patients with type 2 diabetes mellitus. The Nurse Practitioner 42:11, pages 36-42.
Crossref
Crossref
Berhanu Alemayehu, Jinan Liu, Swapnil Rajpathak & Samuel S. Engel. (2017) Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. Journal of Diabetes and its Complications 31:11, pages 1620-1623.
Crossref
Crossref
Mehul R. Dalal, Mahmood Kazemi, Fen Ye & Lin Xie. (2017) Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization. Advances in Therapy 34:9, pages 2083-2092.
Crossref
Crossref
Ildiko LingvayJason ChaoMehul R. DalalLuigi F. Meneghini. (2017) Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. Diabetes Technology & Therapeutics 19:5, pages 315-322.
Crossref
Crossref
Pamela C. Heaton, Vibha C. A. Desai, Christina M. L. Kelton & Swapnil N. Rajpathak. (2016) Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Ariane K. Kawata, Hilary Wilson, Siew Hwa Ong, Karoly Kulich & Karin Coyne. (2016) Development and Psychometric Evaluation of the Hypoglycemia Perspectives Questionnaire in Patients with Type 2 Diabetes Mellitus. The Patient - Patient-Centered Outcomes Research 9:5, pages 395-407.
Crossref
Crossref
Bruce C. Stuart, Xian Shen, Charlene C. Quinn, Nicole Brandt, Pamela Roberto, F. Ellen Loh, Franklin Hendrick, Caroline Kim, Xingyue Huang & Swapnil Rajpathak. (2016) Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents. Journal of Managed Care & Specialty Pharmacy 22:9, pages 1019-1027.
Crossref
Crossref
Marie L. Davies, David Q. Pham & Scott R. Drab. (2016) GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:8, pages 893-905.
Crossref
Crossref
Yi-Jing Sheen & Wayne H.H. Sheu. (2016) Association between hypoglycemia and dementia in patients with type 2 diabetes. Diabetes Research and Clinical Practice 116, pages 279-287.
Crossref
Crossref
Charles E. Leonard, Xu Han, Warren B. Bilker, James H. Flory, Colleen M. Brensinger, David A. Flockhart, Joshua J. Gagne, Serena Cardillo & Sean Hennessy. (2016) Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Research and Clinical Practice 115, pages 60-67.
Crossref
Crossref
Richa Redhu Gehlaut, Godwin Y. Dogbey, Frank L. Schwartz, Cynthia R. Marling & Jay H. Shubrook. (2015) Hypoglycemia in Type 2 Diabetes - More Common Than You Think. Journal of Diabetes Science and Technology 9:5, pages 999-1005.
Crossref
Crossref
Swapnil N. Rajpathak, Chunmay Fu, Kimberley Brodovicz, Samuel S. Engel & Pamela C. Heaton. (2015) Sulfonylurea monotherapy and emergency room utilization among elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice 109:3, pages 507-512.
Crossref
Crossref
JM. Amate, T. Lopez‐Cuadrado, N. Almendro, C. Bouza, Z. Saz‐Parkinson, R. Rivas‐Ruiz & J. Gonzalez‐Canudas. (2015) Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis. International Journal of Clinical Practice 69:3, pages 292-304.
Crossref
Crossref
Linong Ji, Juming Lu, Jianping Weng, Weiping Jia, Haoming Tian, Dalong Zhu, Xiaoping Xing & Lixin Guo. (2015) China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. Journal of Diabetes 7:2, pages 166-173.
Crossref
Crossref
Geoffrey D. BraatvedtAdrian J. SykesZaven PanossianDianna McNeill. (2014) The Clinical Course of Patients with Type 2 Diabetes Presenting to the Hospital with Sulfonylurea-Induced Hypoglycemia. Diabetes Technology & Therapeutics 16:10, pages 661-666.
Crossref
Crossref
Javier Morales & Doron Schneider. (2014) Hypoglycemia. The American Journal of Medicine 127:10, pages S17-S24.
Crossref
Crossref
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey & Michelle A. Baron. (2014) Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. Journal of Diabetes and its Complications 28:3, pages 393-398.
Crossref
Crossref
J. Seufert, H. Brath, S. Pscherer, A. Borck, P. Bramlage & T. Siegmund. (2014) Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients. Diabetes, Obesity and Metabolism 16:3, pages 248-254.
Crossref
Crossref
Silvia Paz, Diego González Segura, Anna Raya Torres & Luis Lizan. (2014) Principales factores asociados al coste de la diabetes mellitus tipo 2: revisión de la literatura. Avances en Diabetología 30:2, pages 34-44.
Crossref
Crossref
A. Penfornis, I. Bourdel-Marchasson, S. Quéré & S. Dejager. (2014) Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d’un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine. Médecine des Maladies Métaboliques 8:1, pages 47-55.
Crossref
Crossref
Francisco Javier Ampudia-Blasco. (2014) Aspectos clínicamente relevantes para pacientes diabéticos en tratamiento con insulina: prevención de hipoglucemias y flexibilidad en la administración. Avances en Diabetología 30:1, pages 1-8.
Crossref
Crossref
Hannele Yki-Järvinen, Julio Rosenstock, Santiago Durán-Garcia, Sabine Pinnetti, Sudipta Bhattacharya, Sandra Thiemann, Sanjay PatelHans-Juergen Woerle. (2013) Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. Diabetes Care 36:12, pages 3875-3881.
Crossref
Crossref
Jaime A. Davidson. (2013) Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy 4:2, pages 221-238.
Crossref
Crossref
Pedro Mezquita-Raya, Rebeca Reyes-García, Óscar Moreno-Pérez, Manuel Muñoz-Torres, Juan Francisco Merino-Torres, Juan José Gorgojo-Martínez, Esteban Jódar-Gimeno, Javier Escalada San Martín, Manuel Gargallo-Fernández, Alfonso Soto-Gonzalez, Noemí González Pérez de Villar, Antonio Becerra Fernández, Diego Bellido Guerrero, Marta Botella-Serrano, Fernando Gómez-Peralta & Martín López de la Torre Casares. (2013) Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente concon diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición. Endocrinología y Nutrición 60:9, pages 517.e1-517.e18.
Crossref
Crossref
Pedro Mezquita-Raya, Rebeca Reyes-García, Óscar Moreno-Pérez, Manuel Muñoz-Torres, Juan Francisco Merino-Torres, Juan José Gorgojo-Martínez, Esteban Jódar-Gimeno, Javier Escalada San Martín, Manuel Gargallo-Fernández, Alfonso Soto-Gonzalez, Noemí González Pérez de Villar, Antonio Becerra Fernández, Diego Bellido Guerrero, Marta Botella-Serrano, Fernando Gómez-Peralta & Martín López de la Torre Casares. (2013) Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition. Endocrinología y Nutrición (English Edition) 60:9, pages 517.e1-517.e18.
Crossref
Crossref
Anthony H Barnett, Holger Huisman, Russell Jones, Maximilian von Eynatten, Sanjay Patel & Hans-Juergen Woerle. (2013) Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. The Lancet 382:9902, pages 1413-1423.
Crossref
Crossref
Burkhard Göke, Baptist Gallwitz, Johan G. Eriksson, Åsa Hellqvist & Ingrid Gause-Nilsson. (2013) Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. International Journal of Clinical Practice 67:4, pages 307-316.
Crossref
Crossref
R. E. Ratner, S. C. L. Gough, C. Mathieu, S. Del Prato, B. Bode, H. Mersebach, L. Endahl & B. Zinman. (2012) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials. Diabetes, Obesity and Metabolism 15:2, pages 175-184.
Crossref
Crossref
A. Penfornis, I. Bourdel-Marchasson, S. Quere & S. Dejager. (2012) Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes & Metabolism 38:6, pages 550-557.
Crossref
Crossref
Kohei Kaku, Masashi Hirayama & Emiko Komura. (2012) Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus. Combination Products in Therapy 2:1.
Crossref
Crossref